Abstract: The present disclosure provides an anhydrous solution that includes between 5% and 15% w/w of gibberellic acid (GA3) in a solvent, where the solvent consists of: (a) isopropanol; (b) up to 10% w/w of methanol, ethanol, or a combination thereof; (c) up to 10% w/w of dimethyl sulfoxide (DMSO); and (d) up to 50% w/w of n-propanol, tetrahydrofurfuryl alcohol (THFA), or a combination thereof. The disclosure also provides methods of making such solutions.

Abstract: An implantable drug delivery device includes a proximal portion, a distal portion, and an elongate portion disposed between the proximal portion and the distal portion. The proximal portion is angled, relative to the elongate portion. The distal portion is angled, relative to the elongate portion. The drug delivery device is configured for insertion into a punctum of an eye, such that at least the distal portion and the elongate portion fully reside in the punctum of the eye when the drug delivery device is inserted.

Abstract: A punctum plug or lacrimal insert is constructed of a monolithic material, such that the punctum plug is configured to turn approximately 90 degrees upon insertion into a canaliculus of an eye. The punctum plug or lacrimal insert may include high-molecular-weight polysaccharide and added plasticizers.

Abstract: The present invention is a highly concentrated plant growth regulator suspended in a solid, semisolid, paste, gel, etc. that allows for targeted application and extended, continuous release of the plant growth regulator in the targeted growth-related areas of the plant/tree. The carrier medium is dosed with one or more particulate PGRs, and possibly a fungicide or insecticide, and this composition results in not only a highly effective way to achieve growth, but also allows for a very unique application and benefit on grafted trees by sealing the graft wound and accelerating the regrowth either alone or in combination with traditional treatments. Additionally, the present invention can be used to seal pruning wounds that farmers heretofore have used Latex type products.

Abstract: The present disclosure provides an anhydrous solution that includes between 5% and 15% w/w of gibberellic acid (GA3) in a solvent, where the solvent consists of: (a) isopropanol; (b) up to 10% w/w of methanol, ethanol, or a combination thereof; (c) up to 10% w/w of dimethyl sulfoxide (DMSO); and (d) up to 50% w/w of n-propanol, tetrahydrofurfuryl alcohol (THFA), or a combination thereof. The disclosure also provides methods of making such solutions.

Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.

Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.

Abstract: Electrochemical sensors for measuring an analyte in a subject are described. More particularly, devices for measurement of an analyte incorporating a sensor comprising a hydrophilic polymer-enzyme composition covering an electroactive surface providing rapid and accurate analyte levels upon deployment are disclosed.

Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion is for binding to necrotic tissue in the subject.

Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.

Abstract: Electrochemical sensors for measuring an analyte in a subject are described. More particularly, devices for measurement of an analyte incorporating a sensor comprising a hydrophilic polymer-enzyme composition covering an electroactive surface providing rapid and accurate analyte levels upon deployment are disclosed.

Abstract: A flexible circuit is provided herein that includes conductive material on the top and bottom planar surfaces of a dielectric substrate. The flexible circuit can be used in various applications, including use as a sensor. A via is used to provide electrical communication between the top and bottom surface of the flexible circuit. A method of preparing a flexible circuit and a medical instrument including the flexible circuit are also provided.

Abstract: There are provided methods of packaging and packages that prevent damage of the package contents while maintaining sterility and that limit the negative effects of sterilization on sensors such as enzyme sensors. A method of packaging an enzyme sensor includes providing an enzyme sensor such as a glucose oxidase sensor in a gas impermeable package comprising one or more of oxygen and water, removing a significant portion of the oxygen and water present in the package, and sealing the package. The resulting package comprises the enzyme sensor in an atmosphere that is substantially free of oxygen and water. The package can also include a pressure indicator that indicates when the package has exceeded a predetermined pressure.

Abstract: A temperature compensation method for an enzyme electrode by measuring an operating temperature of the enzyme electrode, measuring the current generated by the enzyme electrode determining a deviation in measurement between the current generated and a reference current at the operating temperature, determining an enzyme concentration corresponding to the measured current, and calibrating the enzyme concentration to compensate for the deviation in measurement.

Abstract: A hydrogel for an intravenous amperometric biosensor is formed on an electrode from a matrix of chitosan and a cross-linking agent, such as genipin to immobilize a reactive agent such as glucose oxidase. The matrix may also function as a rate-limiting layer to selectively control diffusion to the reactive agent. A method for forming the hydrogel on an electrode for immobilizing a reactive agent may include dissolving chitosan in an acidic solution, adding the reactive agent, applying solution to the electrode surface, curing the solution to a solid film, and immersing the same in a genipin buffer.

Abstract: A single or multilumen intravenous catheter that may include an integral biosensor having an active portion exposed through a sensing port formed in a distal portion of an outer wall of the catheter. The biosensor may be formed on a flex circuit mounted to a support member or probe that displaces the active portion from an inner wall of the catheter for protection from friction during installation through a lumen. The support member or probe may position the biosensor concentrically within the lumen or against an inner diameter of the outer wall. The biosensor may be sealed about the sensing port to prevent passage of fluid therethrough, or a proximal end of the sensing port may remain open to allow flushing of the biosensor with saline infused through the lumen.

Abstract: The present invention relates to therapeutically active 2-aminoindane analogs of formula (I): Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

Abstract: The present invention relates to therapeutically active cubane compounds, a method of preparing the same, and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating and preventing diseases of the central nervous system related to the metabotropic glutamate receptor system.

Abstract: The present invention relates to therapeutically active cubane compounds, a method of preparing the same, and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

Abstract: The present invention relates to therapeutically active novel aminoindanes of formula (I). Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.